Home › Non-Hodgkin Lymphoma › North Carolina › Durham
Non-Hodgkin Lymphoma clinical trials in Durham, NC
16 studies for Non-Hodgkin Lymphoma are looking for participants at sites in and around Durham (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecruitingPhase 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · 10 mi away
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
RecruitingObservational study
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecruitingPhase 3
- Duke Cancer Institute, Durham
DALY II USA/ MB-CART2019.1 for DLBCL
RecruitingPhase 2
- Duke University Medical Center - Division of Hematologic Malignancies, Durham
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi away
Registry of Older Patients With Cancer
RecruitingObservational study
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi away
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RecruitingPhase 1
- University of North Carolina, Chapel Hill · 10 mi away
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RecruitingPhase 1/2
- Duke University Medical Center, Duke Cancer Center, Durham
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RecruitingPhase 4
- Duke University Medical Center, Durham
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RecruitingPhase 4
- Duke University Medical Center, Durham
Study of SGR-1505 in Mature B-Cell Neoplasms
RecruitingPhase 1
- Duke University, Durham
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
RecruitingPhase 1
- Duke University, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi away
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi away
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
RecruitingPhase 1
- University of North Carolina, Chapel Hill · 10 mi away
Non-Hodgkin Lymphoma trials in other cities
- Houston, TX31 studies
- New York City, NY31 studies
- Boston, MA26 studies
- Nashville, TN21 studies
- Philadelphia, PA20 studies
- Baldwin Park, CA19 studies
- Washington, DC18 studies
- Atlanta, GA18 studies
- Milwaukee, WI18 studies
- Chicago, IL18 studies
- Columbus, OH18 studies
- Dallas, TX17 studies
Other studies in Durham
- Breast Cancer64 studies
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer39 studies
- Multiple Myeloma37 studies
- Acute Myeloid Leukemia33 studies
- Metastatic Cancer33 studies
- Prostate Cancer32 studies
- Lung Cancer32 studies
- Colorectal Cancer28 studies
- Ovarian Cancer27 studies
- Chronic Lymphocytic Leukemia27 studies
- Heart Failure26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.